Bilateral sequential and simultaneous rhegmatogenous retinal detachments: anatomic and functional outcomes

Sihame Doukkali; Mélanie Hébert; Eunice You; Serge Bourgault; Mathieu Caissie; Éric Tourville; Ali Dirani

doi:10.1016/j.jcjo.2023.07.022

Bilateral sequential and simultaneous rhegmatogenous retinal detachments: anatomic and functional outcomes

Can J Ophthalmol. 2023 Aug 26:S0008-4182(23)00245-4. doi: 10.1016/j.jcjo.2023.07.022. Online ahead of print.

Authors

Sihame Doukkali¹, Mélanie Hébert², Eunice You², Serge Bourgault², Mathieu Caissie², Éric Tourville², Ali Dirani³

Affiliations

¹ Faculty of Medicine, Laval University, Quebec, QC.
² Department of Ophthalmology, Hospital Saint-Sacrement, Laval University, Quebec, QC.
³ Department of Ophthalmology, Hospital Saint-Sacrement, Laval University, Quebec, QC. Electronic address: drdirani@gmail.com.

PMID: 37640227
DOI: 10.1016/j.jcjo.2023.07.022

Abstract

Objective: To assess the anatomic and functional outcomes in sequential and simultaneous bilateral rhegmatogenous retinal detachment (BRRD) repair.

Design: Retrospective cohort study.

Participants: A total of 218 eyes in 109 patients.

Methods: Patients diagnosed with BRRD between 2014 and 2020 at the University Centre of Ophthalmology-CHU de Québec-Laval University were reviewed. Main outcomes were single-surgery anatomic success (SSAS) and final pinhole visual acuity (PHVA) in logMARs.

Results: Of the 109 patients, 86 (79%) were male, and median (Q1, Q3) age at presentation for the first eye was 60 years (range, 54-66 years). Of these patients, 92% (n = 100) had sequential BRRD and 8% (n = 9) simultaneous BRRD. Median (Q1, Q3) duration of symptoms was shorter for second eyes (first, 7 days [range, 3-15 days] vs second, 4 days [range, 2-10 days]; p = 0.028). Second eyes also had less retinal tears (first, 2.94 ± 2.76 tears vs second, 2.38 ± 1.79 tears; p = 0.031) and better median preoperative PHVA (first, 0.46 logMAR [range, 0.14-2.30 logMAR] vs second, 0.24 logMAR [range, 0.06-0.95 logMAR]; p = 0.012). SSAS was achieved in 100 (92%) and 101 (93%) of first and second eyes, respectively (p = 1.00). Final PHVA was better for the first eye (first, 0.14 logMAR [range, 0.04-0.30 logMAR] vs second, 0.20 logMAR [range, 0.04-0.43 logMAR]; p = 0.010) but comparable at 3 months (first, 0.30 logMAR [range, 0.14-0.48 logMAR] vs second, 0.34 logMAR [range, 0.13-0.70 logMAR]; p = 0.36).

Conclusions: SSAS was similar for both eyes. The subsequent eye was more likely to be treated earlier with less advanced presentations, but at 3 months, PHVA was not significantly different between eyes. Difference in final PHVA may be attributable to longer follow-up in first eyes.